Skip to main content
Premium Trial:

Request an Annual Quote

MD Anderson, Orionis Biosciences Ink Partnership to Advance, Repurpose Small-Molecule Cancer Drugs

NEW YORK – Orionis Biosciences and the MD Anderson Cancer Center's Therapeutics Discovery division said on Tuesday that they have teamed up on a research project to advance drug development through genome-scale mapping of drug-target interactions.

The goal of the research collaboration, dubbed Project Helios, is to identify opportunities to develop, optimize, and potentially repurpose treatments using information gleaned from a large collection of drug-target interaction data. The research will initially focus on drugs to address unmet needs in oncology, though it may ultimately branch into other therapeutic areas.

For its part of the collaboration, Waltham, Massachusetts-based Orionis will contribute its high-throughput drug discovery platforms, while MD Anderson will bring its small-molecule and translational biology expertise. Using a large portfolio of small molecules, including both approved drugs and investigational agents, Project Helios will involve systematically mapping how these drugs interact across the human proteome, potentially leading to discoveries such as ways to repurpose approved therapies, optimize ways to approach known treatment targets, and develop treatments for novel targets. The partnership is "a fundamental step toward new approaches in drug discovery that will enlighten our understanding of the dark proteome," according to Orionis CEO Niko Kley.

"This effort will build on a wealth of public data, chemical and clinical knowledge that has been assembled over many years across the pharmaceutical industry and biomedical institutions," Kley said in a statement.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.